Cooley advised Sucampo Pharmaceuticals on its acquisition of rare disease biotech firm Vtesse for $200 million in cash and stock in upfront payments and contingent payments based on net sales of the acquired product. The purchase provides Sucampo access to VTS-270, a product candidate undergoing study for the treatment of Niemann-Pick Disease Type C1 (NPC).
Key deals, decisions + trends
Close